

REMARKS

Claims 1-6, 8-13 and 15-18 are currently pending. Claims 7 and 14 have been cancelled. Claim 18 has been newly added and claims 1-6, 16 and 17 have been amended. Support for the amendments is provided for in the originally filed claims as well as pages 2, lines 6-20 for claim 16 and page 5, lines 1-6 for claims 1-6. No new matter has been introduced into the application by way of amendment.

Claim Objections:

Claim 2 is objected to because of the term "compounds" in line 1. Claim 2 has been amended rendering the objection moot. Withdrawal of the objection is respectfully requested.

Claims 15-17 are objected to as being improperly multiply dependent. The claims have been amended rendering the objection moot. Withdrawal of the objection is respectfully requested.

Rejection under 35 USC 103(a):

Claims 1-17 are rejected as being unpatentable over Mentrup, et al (US 3,969,410) in view of Remington's Pharmaceutical Sciences, Goodman and Gilman's and Welland, et al.

While not agreeing with the propriety of Examiner's rejection and solely to advance prosecution, claims 1-9, 8-13 and 15-17 have been amended. As the references do not read on the instantly claimed invention, withdrawal of the rejection is respectfully requested.

In view of the above amendments and remarks, Applicants respectfully submit that this application is now in condition for allowance and earnestly request such action.

If any points remain at issue which can best be resolved by way of a telephonic or personal interview, the Examiner is kindly requested to contact the undersigned attorney at the telephone number listed below.

Respectfully submitted,



Andrea D. Small
Attorney for Applicant(s)
Reg. No. 54,859

Patent Department
Boehringer Ingelheim Corp.
900 Ridgebury Road
P.O. Box 368
Ridgefield, CT. 06877
Tel.: (203) 798-4816
Fax: (203) 798-4408